About
Philippe Dro is trained in industrial pharmacy and finance and has worked across the European biotech and medtech sectors. His recent roles include Board member and CBO of Themis Biosciences (acquired by Merck & Co) and CEO and Supervisory Board member of GlycoVaxyn AG (acquired by GSK); earlier he served as CEO and Chairman of Endoart S.A. (acquired by Allergan) and was part of the founding team at Axovan (acquired by Actelion). His earlier pharmaceutical career included management positions at Novartis, SkyePharma, and Antares Pharma.
Invests in
BiotechMedical Devices
Investments
Board seats
Luciole Medical AGScenic Biotech BV
Per the firm's website.
Colleagues at Adjuvant Capital
Abrar Haque
Associate at Adjuvant Capital
Alexandra (Sandra) Glucksmann
Advisory Partner at Adjuvant Capital
Christian Mandl
Senior Advisor at Adjuvant Capital
Curt LaBelle
Venture Partner at Adjuvant Capital
David Washer
Investor at Adjuvant Capital
Evelyn Yanatos
Director of Finance and Compliance at Adjuvant Capital
Gerard Cunningham
Operating Partner at Adjuvant Capital
Giulia Balconi
Associate at Adjuvant Capital